Why the study?
Does the implantable cardioverter-defibrillator improve survival compared to conventional antiarrhythmic drug therapy in patients with or at high risk for serious ventricular arrhythmias?
Population
Patients who have experienced ventricular fibrillation, sustained ventricular tachycardia causing syncope or…
Comparison
Implantable cardioverter-defibrillator (ICD) vs Conventional antiarrhythmic drug therapy
Design
Review
Authors
Loading...
Supports ICD prioritization in high-risk post-MI and arrhythmia patients; leaves open need for contemporary trials with modern therapies.
Does the implantable cardioverter-defibrillator improve survival compared to conventional antiarrhythmic drug therapy in patients with or at high risk for serious ventricular arrhythmias?
The implantable cardioverter-defibrillator represents a major advance in the treatment of ventricular arrhythmias, offering superior survival benefits over antiarrhythmic drugs for specific high-risk patient populations.
H. Leon Greene (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: